SciBase Holding AB (SCIB) AI Stock Analysis

• Market Cap: kr199.64M
• Dividend Yield: N/A
• Average Volume (3M): 318.73K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.10
• Revenue Growth: 36.15%
• EPS Growth: 26.67%
• Country: SE
• Employees: 32
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.04
• Shares Outstanding: 828,365,200
• 10 Day Avg. Volume: 218,776
• 30 Day Avg. Volume: 318,725
• PEG Ratio: 0.04
• Price to Book (P/B): 1.99
• Price to Sales (P/S): 2.46
• P/FCF Ratio: -1.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: kr0.23 ▼(-29.09% Downside)

The score is mainly held back by severe losses and substantial cash burn despite strong revenue growth and solid gross margins. Technical indicators also point to weak momentum with the stock below key moving averages. Valuation provides limited support due to negative earnings and no dividend information.

Positive Factors

Revenue Growth Momentum

High trailing revenue growth (~36%) indicates accelerating clinical adoption of Nevisense and expanding market traction. Durable top-line momentum supports installed-base expansion, which drives recurring consumable and service revenue and improves leverage of fixed costs over months.

Strong Product-Level Margins

Sustained gross margin around 66% suggests favorable unit economics for the Nevisense platform. Strong product margins provide a structural buffer as sales scale, improving the potential to cover operating costs and move toward profitability if commercial momentum continues.

Low Financial Leverage

Very low debt relative to equity reduces solvency risk and preserves financial flexibility. This structural balance-sheet strength gives management room to fund commercialization and clinical expansion via equity or selective financing without heavy near-term interest burdens.

Negative Factors

Severe Cash Burn

Trailing twelve-month operating and free cash flows are deeply negative (~-76M), signaling persistent cash burn. That reliance on external funding constrains strategic options, increases dilution risk, and threatens the company's ability to sustain investments absent financing.

Deep Operating and Net Losses

Operating and net margins are materially negative, with costs far outpacing revenue. These structural losses imply the business cannot convert growth into profitability without significant cost reductions or much faster revenue scaling over the coming quarters.

Negative Returns and Equity Erosion

Very negative ROE (~-249%) indicates shareholder value is being eroded by ongoing losses. Continued negative returns degrade the equity base over time, raising the likelihood of future capital raises and dilution, and signaling persistent sustainability challenges.

SciBase Holding AB Business Overview & Revenue Model

Company Description

SciBase Holding AB (SCIB) is a Swedish medical technology company that specializes in developing innovative diagnostic solutions for skin cancer detection and monitoring. The company operates primarily in the healthcare sector, focusing on non-invasive and effective diagnostic tools. Its core products leverage advanced technology, particularly electrical impedance spectroscopy, to provide dermatologists and healthcare providers with real-time information to aid in the diagnosis of skin lesions, ultimately enhancing patient outcomes.

How the Company Makes Money

SciBase generates revenue primarily through the sale of its diagnostic devices and related services. The company's key revenue streams include the direct sale of its flagship product, Nevisense, which is used for the early detection of melanoma and other skin cancers. Additionally, SciBase earns revenue from consumables associated with the use of its devices, as well as software and support services that accompany its diagnostic solutions. The company has established partnerships with healthcare institutions and dermatology clinics, which help expand its market reach and drive sales. Furthermore, ongoing research and development efforts aim to enhance product offerings and create new revenue opportunities through potential future products and applications in the dermatology space.

SciBase Holding AB Financial Statement Overview

Summary

SciBase Holding AB shows promising revenue growth and a solid equity base, but struggles with profitability and cash flow sustainability. The absence of long-term debt reduces financial risk, yet continuous net losses and cash burn are significant concerns.

Income Statement

SciBase Holding AB has shown consistent revenue growth over the years, with a notable improvement from SEK 9.52M in 2020 to SEK 29.71M in 2024. Despite this positive trend, the company struggles with profitability, evidenced by negative net profit margins and EBIT margins over the years. The gross profit margin remains relatively strong, suggesting effective cost management at the gross level. However, the persistent operating losses and negative EBITDA highlight ongoing challenges in achieving operational efficiency.

Balance Sheet

The balance sheet indicates a stable equity position with no long-term debt in 2024, which reduces financial risk. The equity ratio is strong, reflecting a solid proportion of funding from shareholders. However, the return on equity is negative due to ongoing net losses, which is a concern for investors. The declining asset base over recent years may indicate potential challenges in asset management or investment.

Cash Flow

Cash flow analysis reveals consistent negative free cash flow, indicating cash burn that is not yet offset by operational activities. The operating cash flow to net income ratio shows a close alignment, suggesting that accounting adjustments are not significantly distorting cash performance. The company has been reliant on financing activities to fund operations, as evidenced by substantial cash inflows from financing in 2024.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	36.58M	29.70M	23.25M	17.89M	11.73M	9.52M
Gross Profit	24.16M	21.08M	16.04M	11.23M	6.58M	5.00M
EBITDA	-64.01M	-57.59M	-51.83M	-39.33M	-38.58M	-32.19M
Net Income	-90.39M	-61.13M	-55.59M	-39.90M	-41.69M	-34.99M
Balance Sheet
Total Assets	53.98M	61.73M	64.33M	49.85M	85.46M	59.25M
Cash, Cash Equivalents and Short-Term Investments	24.76M	11.24M	34.12M	18.83M	65.61M	41.43M
Total Debt	326.00K	4.18M	6.80M	8.12M	2.86M	1.92M
Total Liabilities	20.50M	25.08M	21.28M	24.62M	14.66M	12.39M
Stockholders Equity	33.48M	36.65M	43.06M	25.24M	70.80M	46.86M
Cash Flow
Free Cash Flow	-76.60M	-57.81M	-52.37M	-44.85M	-40.12M	-34.16M
Operating Cash Flow	-76.30M	-57.38M	-51.98M	-44.47M	-39.50M	-33.86M
Investing Cash Flow	-210.00K	-428.00K	-383.00K	-381.00K	-526.00K	858.00K
Financing Cash Flow	76.64M	34.91M	67.68M	-2.48M	64.22M	47.90M

SciBase Holding AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SCIB, the sentiment is Negative. The current price of 0.33 is above the 20-day moving average (MA) of 0.28, above the 50-day MA of 0.26, and above the 200-day MA of 0.30, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.26 is Neutral, neither overbought nor oversold. The STOCH value of 24.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SCIB.

SciBase Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARCOMA	58 Neutral	kr111.32M	24.83	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NEOLA	45 Neutral	kr82.63M	-7.10	―	―	―	―
SCIB	44 Neutral	kr199.64M	-0.96	-253.54%	―	36.15%	26.67%
CLS.B	44 Neutral	kr255.57M	-4.70	-63.39%	―	14.18%	72.73%
ICO	42 Neutral	kr58.90M	-0.77	―	―	-45.59%	37.79%
LXB	38 Underperform	kr62.34M	-2.62	-60.20%	―	163.12%	30.50%